Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Successful completion of $30.0m financing package

April 8, 2022
RNS Number : 7737H Renalytix PLC 08 April 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

$30.0 million financing package

March 31, 2022
RNS Number : 7325G Renalytix PLC 31 March 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR

Half-year Report

March 31, 2022
RNS Number : 6807G Renalytix PLC 31 March 2022       Renalytix plc ("Renalytix" or the "Company")   Half Year Report   LONDON and SALT LAKE CITY , March 31, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE : RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing

Timothy Scannell appointed to the Board

March 30, 2022
RNS Number : 5577G Renalytix PLC 30 March 2022     Renalytix plc ("Renalytix" or the "Company")   Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors   NEW YORK and SALT LAKE CITY , March 30, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX) announces that, following the

Enrollment Milestone for KidneyIntelX

March 29, 2022
RNS Number : 3159G Renalytix PLC 29 March 2022   Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes   KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched

Notice of Results

March 25, 2022
RNS Number : 9571F Renalytix PLC 25 March 2022     Renalytix plc ("Renalytix" or the "Company")   Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31   NEW YORK and SALT LAKE CITY , March 25, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today

Renalytix Launches myIntelX

March 9, 2022
RNS Number : 1092E Renalytix PLC 09 March 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform   myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health , and will

Presentation of new clinical data for KidneyIntelX

February 24, 2022
RNS Number : 6330C Renalytix PLC 24 February 2022     KidneyIntelX TM Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care   Data highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney

RENX to Present at Cowen 42nd Annual Conference

February 22, 2022
RNS Number : 3488C Renalytix PLC 22 February 2022       Renalytix plc ("Renalytix" or the "Company")   Renalytix to Present at Cowen 42 nd Annual Health Care Conference   New York and SALT LAKE CITY , February 22, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) ("Renalytix" or the "Company") today

Timothy Scannell to be appointed to board

February 22, 2022
RNS Number : 3394C Renalytix PLC 22 February 2022     Renalytix plc ("Renalytix" or the "Company")   Renalytix to Appoint Timothy Scannell to Board of Directors NEW YORK, NY and SALT LAKE CITY, UT   February 22, 2022 - Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) today announced its intention to
Displaying 11 - 20 of 205